Poseida and Roche to develop cell therapies for hematologic cancers
Poseida could get research, development, launch and net sales milestones and other payments totalling up to $6bn.

Poseida could get research, development, launch and net sales milestones and other payments totalling up to $6bn.
The clinical trial of GreenLight’s Covid-19 booster vaccine is anticipated to commence this year.
The parties aim to manufacture vaccines with lasting immune responses compared to existing ones.
The initial 66 million vaccine doses are anticipated to be supplied this year.
In Phase II/III KidCOVE trial, the vaccine offered a strong neutralising antibody response in children.
In Phase II/III KidCOVE trial, two doses of the vaccine offered strong neutralising antibody response in the young children.
Avrobio is expected to initiate a Phase I/II clinical trial for Hunter syndrome in partnership with the University of Manchester.
The ACT platform will be commissioned to manufacture raw materials for the subsequent pipeline of ACT.
Thank you for subscribing to Pharmaceutical Technology